6,7-Dichloro-5-(1-[1,2,4]triazol-1-yl-propyl)-1,4-dihydro-quinoxaline-2,3-dione

ID: ALA62164

Chembl Id: CHEMBL62164

PubChem CID: 10617091

Max Phase: Preclinical

Molecular Formula: C13H11Cl2N5O2

Molecular Weight: 340.17

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CCC(c1c(Cl)c(Cl)cc2nc(O)c(O)nc12)n1cncn1

Standard InChI:  InChI=1S/C13H11Cl2N5O2/c1-2-8(20-5-16-4-17-20)9-10(15)6(14)3-7-11(9)19-13(22)12(21)18-7/h3-5,8H,2H2,1H3,(H,18,21)(H,19,22)

Standard InChI Key:  LSDAVLIROZXVMY-UHFFFAOYSA-N

Associated Targets(non-human)

Grin1 Glutamate NMDA receptor (6467 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 340.17Molecular Weight (Monoisotopic): 339.0290AlogP: 2.94#Rotatable Bonds: 3
Polar Surface Area: 96.95Molecular Species: NEUTRALHBA: 7HBD: 2
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 11.14CX Basic pKa: 1.95CX LogP: 3.49CX LogD: 3.49
Aromatic Rings: 3Heavy Atoms: 22QED Weighted: 0.76Np Likeness Score: -1.11

References

1. Fray MJ, Bull DJ, Carr CL, Gautier EC, Mowbray CE, Stobie A..  (2001)  Structure-activity relationships of 1,4-dihydro-(1H,4H)-quinoxaline-2,3-diones as N-methyl-D-aspartate (glycine site) receptor antagonists. 1. Heterocyclic substituted 5-alkyl derivatives.,  44  (12): [PMID:11384240] [10.1021/jm001124p]
2. Das B, Baidya ATK, Mathew AT, Yadav AK, Kumar R..  (2022)  Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.,  56  [PMID:35033884] [10.1016/j.bmc.2022.116614]

Source